Taken together, our findings were consistent with the model whereby elevated G9a in breast cancer allows aberrant hypermethylation of the HEPH promoter, suppressing HEPH transcription, which then increases intracellular LIP and drives breast tumor progression. The gene discussed is EHMT2; the disease is breast carcinoma.